Related references
Note: Only part of the references are listed.A comment on ion channels as pharmacological targets in oncology
Andrea Becchetti et al.
JOURNAL OF GENERAL PHYSIOLOGY (2008)
Roscovitine, a cyclin-dependent kinase inhibitor, affects several gating mechanisms to inhibit cardiac L-type (Ca(V) 1.2) calcium channels
V. Yarotskyy et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
VEGFR-1 (FLT-1), β1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia:: role in cell migration and clinical outcome
Serena Pillozzi et al.
BLOOD (2007)
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
C. Benson et al.
BRITISH JOURNAL OF CANCER (2007)
Roscovitine differentially affects CaV2 and Kv channels by binding to the open state
Zafir Buraei et al.
NEUROPHARMACOLOGY (2007)
Molecular determinants of hERG channel block
K Kamiya et al.
MOLECULAR PHARMACOLOGY (2006)
hERG potassium channels and cardiac arrhythmia
MC Sanguinetti et al.
NATURE (2006)
Potassium channels: New targets in cancer therapy
Antonio Felipe et al.
CANCER DETECTION AND PREVENTION (2006)
hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines
A Masi et al.
BRITISH JOURNAL OF CANCER (2005)
Slowed N-type calcium channel (CaV2.2) deactivation by the cyclin-dependent kinase inhibitor roscovitine
Z Buraei et al.
BIOPHYSICAL JOURNAL (2005)
HERG K+ channel expression-related chemosensitivity in cancer cells and its modulation by erythromycin
SZ Chen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Role of voltage-gated potassium channels in cancer
LA Pardo et al.
JOURNAL OF MEMBRANE BIOLOGY (2005)
Neurotoxic calcium transfer from endoplasmic reticulum to mitochondria is regulated by cyclin-dependent kinase 5-dependent phosphorylation of tau
F Darios et al.
JOURNAL OF NEUROSCIENCE (2005)
Inherited and acquired vulnerability to ventricular arrhythmias: Cardiac Na+ and K+ channels
CE Clancy et al.
PHYSIOLOGICAL REVIEWS (2005)
Structural determinants of HERG channel block by clofilium and ibutilide
M Perry et al.
MOLECULAR PHARMACOLOGY (2004)
Direct block of hERG potassium channels by the protein kinase C inhibitor bisindolylmaleimide I (GF109203X)
D Thomas et al.
CARDIOVASCULAR RESEARCH (2004)
Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652
JT Milnes et al.
BRITISH JOURNAL OF PHARMACOLOGY (2003)
Modulation of human ether-a-go-go-related K+ (HERG) channel inactivation by Cs+ and K+
ST Zhang et al.
JOURNAL OF PHYSIOLOGY-LONDON (2003)
Spironolactone and its main metabolite, canrenoic acid, block human ether-a-go-go-related gene channels
R Caballero et al.
CIRCULATION (2003)
HERG potassium channels are constitutively expressed in primary human acute myeloid leukemias and regulate cell proliferation of normal and leukemic hemopoietic progenitors
S Pillozzi et al.
LEUKEMIA (2002)
The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels
D Thomas et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Indirubins inhibit glycogen synthase kinase-3β and CDK5/P25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease -: A property common to most cycline-dependent kinase inhibitors?
S Leclerc et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
A structural basis for drug-induced long QT syndrome
JS Mitcheson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Apparent change in ion selectivity caused by changes in intracellular K+ during whole-cell recording
CJ Frazier et al.
BIOPHYSICAL JOURNAL (2000)
Share Paper
